Nestlé Health Science and Takeda participated in a series E round for Enterome, which received $52.6m in equity and debt financing through the deal.
France-based microbiome-focused therapy developer Enterome has closed $52.6m in financing, including series E equity funding featuring pharmaceutical firm Takeda and food producer Nestlé.
The series E portion was led by microbiome investment vehicle Symbiosis and included Seventure Partners and its Health for Life Capital fund, Principia and Omnes Capital. Nestlé participated through its nutritional health division, Nestlé Health Science.
The company said it has made its first drawdown from a $48.2m loan facility agreed with the European Union-owned European Investment…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
